PHARMA WIN

Hikma won an appeal to market its gout treatment in the US. It began marketing its colchicine drug in the US as branded product Mitigare in January 2015.

Rival Takeda alleged Mitigare infringed patents related to its own colchicine product, Colcrys.

Takeda lost a court decision and appealed but on Thursday Hikma announced it had won the appeal.